Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

NCT Number	NCT00722228
Lead Sponsor	Hadassah Medical Organization
Conditions	Colorectal Cancer, Ovarian Cancer, Gastric Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Melanoma
Enrollment	50 participants
Start Date	2008-07
Primary Completion	2025-03 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-02